SARS-CoV-2 Clearance from Andrographis paniculata, Boesenbergia rotunda, and Favipiravir among Mild COVID-19 Cases in Klong Prem Central Prison during Mid-2021: a Retrospective Study
Preecha Prempree, Anek Mungaomklang, Mayuree Tangkiatkumjai, Tuangrat Phodha, Pakakrong Kwankhao, Kanokwan Chewchuapun, Chutima Charuenporn, Darika Monta, Thanawut Karapakdee
This study aims to assess the effectiveness of two herbal medicines, Andrographis paniculata (Burm.f.) Nees capsule (AP) and Boesenbergia rotunda (Linn.) Mansf. extract capsule (BR), on the rate of SARS-CoV-2 virus clearance among inmates of Klong Prem Central Prison, Bangkok. Cases with mild COVID-19 were allocated into four groups: four capsules of AP thrice daily (n=30), one capsule of BR once daily (n=30), a combination of AP and BR (AP-BR) (n=30), or favipiravir (n=30) for five days. The primary outcome was time until undetected SARS-CoV-2 infection after starting treatment. The median period of SARS-CoV-2 clearance was shorter in the AP and AP-BR groups (9 days) compared to the BR (11 days) and favipiravir (13 days) groups. No one developed pneumonia; however, one participant in the AP group developed hyperkalemia. Our results suggest that A. paniculata with or without B. rotunda may be used as an alternative treatment for mild COVID-19 when access to favipiravir is limited. Further clinical trials are needed to determine their efficacy and safety.
Authors' Contributions PP guided and revised the manuscript. AM and PK revised the manuscript. MT analyzed study data and wrote the first draft of the manuscript. TP analyzed study data. KC, CC, DM, and TK carried out the research. All authors approved the final manuscript.
References
Bethesda, Md), ClinicalTrials.gov; 2021 [cited
Hu, Wu, Logue, Blondel, Lai et al., Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis
Kanjanasirirat, Suksatu, Manopwisedjaroen, Munyoo, Tuchinda et al., High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. Sci Rep,
doi:10.1038/s41598-020-77003-3Numthavaj, Andrographis paniculata vs Boesenbergia rotunda vs control in asymptomatic COVID-19
Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world effectiveness and optimal dosage of favipiravir for treatment of COVID-19: results from a multicenter observational study in Thailand, Antibiotics (Basel),
doi:10.3390/antibiotics11060805Sa-Ngiamsuntorn, Suksatu, Pewkliang, Thongsri, Kanjanasirirat et al., Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives, J Nat Prod
Shu, He, Sun, Lin, Lu et al., Factors influencing viral clearance in mild COVID-19 and clinical characteristics of asymptomatic participants, Biomed Res Int,
doi:10.1155/2021/5909612Tanwettiyanont, Piriyachananusorn, Sangsoi, Boonsong, Sunpapoa et al., Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised participants with mild coronavirus disease 2019: a retrospective cohort study, Front Med (Lausanne),
doi:10.3389/fmed.2022.947373Ucan, Cerci, Efe, Akgun, Ozmen et al., Benefits of treatment with favipiravir in hospitalized participants for COVID-19: a retrospective observational casecontrol study, Virol J,
doi:10.1186/s12985-021-01577-1Wanaratna, Leethong, Inchai, Chueawiang, Sriraksa et al., Efficacy and safety of Andrographis paniculata extract in participants with mild COVID-19: a randomized controlled trial, Arch Intern Med Res,
doi:10.26502/aimr.0125Zhang, Lv, Zhou, Xie, Xu et al., Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, openlabel and randomized controlled trial, Phytother Res,
doi:10.1002/ptr.7141
